The Newcastle Herald features Immvirx on its work to develop cutting-edge cancer therapies

Hunter-based biotech team ImmVirX is working on a private venture aiming to develop cutting-edge cancer therapies. ImmVirX was established with support from the University of Newcastle Research Associates, recruiting key research staff who were pivotal in Viralytics' medical and commercial success.

The University of Newcastle's Professor Darren Shafren is the Chief Scientific Officer and Dr Malcolm McColl has been reappointed as Managing Director and CEO.

The company's name is an amalgamation of Immuno-oncology, Virus and X (combination therapy).

Read the full story here

Continue reading

Join Our Mailing List

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect